Navigation Links
LaVoie Group Selected by Vaccine Developer, Profectus BioSciences, as Agency of Record

SALEM, Mass., April 29 /PRNewswire/ -- LaVoie Group, a life science-focused strategic communications agency, announced today that it has been selected as public relations agency of record by therapeutic vaccine development company, Profectus BioSciences, Inc.

Donna L. LaVoie, President & CEO of LaVoie Group, commented, "We are delighted to represent Profectus during an important stage in the company's clinical development. We look forward to working with them to communicate their message to appropriate investors, media, pharmaceutical partners and physicians."

Shawn Patrick O'Brien, Chief Executive Officer, commented, "Profectus BioSciences has a strong value proposition since the vaccine sector has emerged as a key revenue generator for big pharma with favorable legislation, relatively low development risk, exemplary commercial success of several blockbuster vaccines, and therapeutic vaccines being more attractive than preventative vaccines. By retaining LaVoie Group, I am confident that we will deliver our message more effectively to our key constituencies."

About Profectus BioSciences, Inc.

Profectus BioSciences is an innovative research and development vaccine company devoted to advancing the treatment and prevention of chronic viral diseases. The Profectus proprietary vaccine design approach combines its pDNA and rVSV platforms via a unique prime boost strategy to enhance immune response. Profectus' broad product pipeline will address Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Human Papilloma Virus (HPV) and Herpes Simplex Virus (HSV).

The Profectus portfolio has received over $100 million in funding from multiple sources including National Institutes of Health (NIH), Cross Atlantic Capital Partners and through private investments. Profectus deploys these resources in support of its proprietary prime boost vaccines and its anti-inflammatory small molecules for cancer and chronic viral diseases. For more information, please visit:

About LaVoie Group, Inc.

LaVoie Group provides senior-level strategic counsel and tactical implementation of venture, investor and public relations programs designed to properly position, create visibility and drive value for each client. We help our life sciences companies attract capital, reach corporate partners, generate revenue and build their companies through integrated communications programs. Our clients range from privately held start-ups to industry leaders in life sciences such as Vertex Pharmaceuticals, ESBATech AG, and Agile Therapeutics.

In March 2009, LaVoie Group was awarded the coveted 2008 Impact Award for "Best Industry-Exclusive Agency," sponsored by the League of American Communications Professionals (LACP). LaVoie Group is ranked by O'Dwyer's PR Report as one of the leading independent healthcare PR firms in the U.S. For more information, please visit

SOURCE LaVoie Group
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
2. Avicena Group to Present at Noble Financial Conference
3. Chrome Group to Seek Listing for Some of its Subsidiaries
4. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
5. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
6. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
7. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
8. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
9. ThirdBiotech Networking Group Launches
10. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
11. Reed Group Ltd. Announces Enterprise License for New Zealands Accident Compensation Corporation
Post Your Comments:
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... While ... machines such as the Cary 5000 and the 6000i models are higher end machines ... is the height of the spectrophotometer’s light beam from the bottom of the cuvette ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):